Balyasny Asset Management
SNDX icon

Balyasny Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Balyasny Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-126,145
Closed -$1.65M – 3431
2025
Q2 		$1.18M Sell
126,145
-1,690,864
-93% -$18.6M ﹤0.01% 1985
2025
Q1 		$22.3M Buy
1,817,009
+1,747,423
+2,511% +$24.6M 0.04% 556
2024
Q4 		$920K Sell
69,586
-297,591
-81% -$5.09M ﹤0.01% 1979
2024
Q3 		$7.07M Buy
+367,177
New +$7.59M 0.01% 1112
2024
Q1 		– Sell
-165,018
Closed -$3.57M – 3085
2023
Q4 		$3.57M Buy
165,018
+16,494
+11% +$254K 0.01% 1249
2023
Q3 		$2.16M Buy
148,524
+48,850
+49% +$924K ﹤0.01% 1360
2023
Q2 		$2.09M Buy
99,674
+80,572
+422% +$1.68M ﹤0.01% 1360
2023
Q1 		$403K Buy
+19,102
New +$475K ﹤0.01% 2009
2018
Q3 		– Sell
-10,413
Closed -$73K – 2005
2018
Q2 		$73K Sell
10,413
-4,400
-30% -$43.2K ﹤0.01% 1724
2018
Q1 		$211K Sell
14,813
-33,993
-70% -$361K ﹤0.01% 1744
2017
Q4 		$428K Buy
+48,806
New +$483K ﹤0.01% 1603

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Balyasny Asset Management's SNDX Position: Q3 2025 in Review

Balyasny Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 126,145 shares — an estimated $1.65M sold.

Balyasny Asset Management first reported a position in SNDX in Q4 2017 and held it in 11 quarters. The position peaked at $22.3M in Q1 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Balyasny Asset Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 126,145 Syndax Pharmaceuticals shares in Q3 2025, an estimated $1.65M.
  • Balyasny Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Balyasny Asset Management's Syndax Pharmaceuticals position peaked at $22.3M in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.